Friday April 8 th 2016
|
|
|
- Miles Morris
- 8 years ago
- Views:
Transcription
1 Preliminary Scientific Program - ICTHIC April 8-10, 2016 Friday April 8 th ,00-11,00 am Industry sponsored session 11,00-11,15 am Congress Opening: A Falanga, FR Rickles, B Brenner 11,15-1,30 pm Plenary Session 1: Epidemiology of thrombosis in cancer Chairs: N Key (USA); TBA - Venous thromboembolism and occult cancer: impact on clinical practice M Carrier (Canada) - Cancer associated thrombosis: risk factors and outcomes S Eichingher (Austria) - Update of incidental VTE in cancer H Liebman (USA) - Thrombosis and anticancer therapies: the contribution of chemotherapy and the specific drugs implicated in CAT P Mismetti (France)
2 2,30-4,45 pm Plenary Session 2: Role of hemostatic pathways in cancer progression Chairs: TBA - Microparticles and cancer thrombosis in animal models C Dubois (France) - Inhibition of platelet function as a target for cancer progression control J Italiano (USA) - Biological basis of personalised anticoagulation in cancer: oncomir networks as regulators of coagulopathy J Rak (Canada) - Heparanase procoagulant activity in cancer progression Y Nadir (Israel)
3 5,15-7,30 pm Plenary Session 3: Old and emerging biomarkers for thrombosis and disease progression in cancer Chairs: B Brenner (Israel); S Kostantinides (Germany) - Cancer-associated thrombosis novel biomarker discovery N Kuderer (USA) - VTE risk assessment models in cancer I Pabinger (Austria) - Polymorphisms of clotting factors and cancer risk P Sandset (Sweeden) - The HYPERCAN prospective study A Falanga (Italy) 7,30 pm Plenary Lecture: 4th Simon Karpatkin Memorial Lecture Chairs: A Falanga (Italy); B Brenner (Israel); FR Rickles (USA) Introduction to Lecture FR Rickles (USA) Targeting clotting proteins in cancer therapy - progress and challenges W Ruf (USA, Germany)
4 Saturday April 9 th ,30-10,45 am Plenary Session 4: Hematological malignancies and hemostatic complications Chairs: TBA - Intracranial hemorrhage in cancer patients on anticoagulation J Zwicker (USA) - Management of cancer-associated disseminated intravascular coagulation M Levi (The Netherlands) - New insights into the biology and management of thrombosis in myeloproliferative neoplasms T Barbui (Italy) - Update of thrombosis in multiple myeloma FWG Leebeek (The Netherlands)
5 11,15 am - 1,30 pm Plenary Session 5: Risk factors for thrombosis in cancer Chairs: I Elalamy (France); GM Liumbruno (Italy) - Upper extremity deep vein thrombosis: comparison between cancer and non-cancer patients SM Bleker (The Netherlands) - Risk of thrombosis and supportive care (transfusion, catheters, growth factors) TBA - New findings from global registries of cancer-associated thrombosis AK Kakkar (UK) - Predictors of recurrent VTE and bleeding on anticoagulation AA Khorana (USA) 2,30-3,00 pm Special Session: History of ICTHIC Chair: H Liebman (USA); A Falanga (Italy); B Brenner (Israel) History of ICTHIC - How has the field progressed since our first meeting in 2001? F Rickles (USA) 3,00-5,00 pm Poster sessions with refreshments Poster walk discussion sessions with chair
6 4,30-6,45 pm Plenary Session 6: Prophylaxis of thrombosis in cancer patients Chairs: TBA Thromboprophylaxis in hospitalized Cancer Patients: a comparison of guidelines M. Levine (USA) Long term cardiovascular complications of chemotherapy in patients with cancer P. W. Kamphuisen (The Netherlands) DOACs in cancer patients - what is known and what are the active trials G Agnelli (Italy)
7 Sunday April 10 th ,30-10,45 am Plenary Session 7: Treatment of cancer-associated thrombosis Chairs: H ten Cate (The Netherlands); G Lyman (USA) - CAT treatment: guidelines update AYY Lee (Canada) - Management of recurrent venous thromboembolism in cancer patients W Ageno (Italy) - The use of vena cava filter in patients with cancer T Wun (USA) - Management of bleeding complications in cancer patients on DOACs S Schulman (Canada)
8 11,15 am - 1,30 pm Plenary session 8: Open questions in cancer and thrombosis Chairs: H Buller (Germany) - Anticoagulant and cancer: Will overall survival increase? HH Veersteg (The Netherlands) - Does one size fit all? Who should get LMWH/warfarin/DOACs? S Noble (UK) - LMWH in cancer patients with renal impairment - better than warfarin? R Bauersachs (Germany) - Laboratory determination of old and new targeted anticoagulant agents for prevention of bleeding and thrombotic events in cancer patients J Harenberg (Germany) 1,30-1,45 pm Concluding Remarks
Novel Oral Anti-coagulants in Patients with Malignancy Lori-Ann Linkins, MD, MSc(Clin Epi), FRCPC McMaster University, Hamilton, ON
Novel Oral Anti-coagulants in Patients with Malignancy Lori-Ann Linkins, MD, MSc(Clin Epi), FRCPC McMaster University, Hamilton, ON Disclosures Speaker honorarium from Bayer (rivaroxaban; Xarelto) and
Thrombose associée au cancer. Prévention et traitement. Guy Meyer Université Paris Descartes Hopital Europeen Georges Pompidou, Paris, France
Thrombose associée au cancer Prévention et traitement Guy Meyer Université Paris Descartes Hopital Europeen Georges Pompidou, Paris, France Conflits d intérêt G Meyer Investigateur: Bayer, Daichi-Sankyo,
DVT/PE Management with Rivaroxaban (Xarelto)
DVT/PE Management with Rivaroxaban (Xarelto) Rivaroxaban is FDA approved for the acute treatment of DVT and PE and reduction in risk of recurrence of DVT and PE. FDA approved indications: Non valvular
Gruppo di lavoro: Malattie Tromboemboliche
Gruppo di lavoro: Malattie Tromboemboliche 2381 Soluble Recombinant Thrombomodulin Ameliorates Hematological Malignancy-Induced Disseminated Intravascular Coagulation More Promptly Than Conventional Anticoagulant
Cancer and the Heparins
WP Ceelen, MD, PhD Department of GI Surgery - UZ Gent Senior Clinical Researcher - FWO Overview Mechanisms of cancer induced thrombosis Guidelines for prevention and treatment of VTE in cancer patients
Bayer Extends Clinical Investigation of Xarelto for the Prevention and Treatment of Life-Threatening Blood Clots in Patients with Cancer
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer Extends Clinical Investigation of Xarelto for the Prevention and Treatment
ABOUT XARELTO CLINICAL STUDIES
ABOUT XARELTO CLINICAL STUDIES FAST FACTS Xarelto (rivaroxaban) is a novel, oral direct Factor Xa inhibitor. On September 30, 2008, the European Commission granted marketing approval for Xarelto for the
Top 10 Thrombosis and Anticoagulation Highlights from ASH 2014
Top 10 Thrombosis and Anticoagulation Highlights from ASH 2014 Stephan Moll, MD UNC School of Medicine, Chapel Hill, NC 1. New Anticoagulant Factor XI lowering drug NEJM publication Dec 7 th (late- breaking
New anticoagulants: Monitoring or not Monitoring? Not Monitoring
The 2 nd World Congress on CONTROVERSIES IN HEMATOLOGY (COHEM) Barcelona, Spain September 6 8, 2012 New anticoagulants: Monitoring or not Monitoring? Not Monitoring Anna Falanga, MD Immunohematology and
Lower extremity DVT See Page 3. Clinical Suspicion of VTE. Pulmonary embolism (PE) See Page 4
Clinical Suspicion of VTE In patients with a high clinical suspicion of DVT/PE, in the absence of contraindications it is recommended that treatment with anticoagulants be started while awaiting the outcome
Attending Physician Attitudes Toward Choice of Oral Anticoagulant for the Treatment of Venous Thromboembolism
Attending Physician Attitudes Toward Choice of Oral Anticoagulant for the Treatment of Venous Thromboembolism NATHAN T. CONNELL, MD, MPH; JAMES N. BUTERA, MD ABSTRACT Until recently, warfarin has been
Prescriber Guide. 20mg. 15mg. Simply Protecting More Patients. Simply Protecting More Patients
Prescriber Guide 20mg Simply Protecting More Patients 15mg Simply Protecting More Patients 1 Dear Doctor, This prescriber guide was produced by Bayer Israel in cooperation with the Ministry of Health as
Bayer Initiates Rivaroxaban Phase III Study to Support Dose Selection According to Individual Benefit-Risk Profile in Long- Term VTE Prevention
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Long-term prevention of venous blood clots (VTE): Bayer Initiates Rivaroxaban
Prior Authorization Guideline
Guideline Guideline Name Formulary Xarelto (rivaroxaban) UnitedHealthcare Community & State Approval Date 0/0/203 Revision Date 8//204 Technician Note: CPS Approval Date: /5/20; CPS Revision Date: 8/20/204
Investor News. Phase III J-ROCKET AF Study of Bayer s Xarelto (rivaroxaban) Meets Primary Endpoint. Not intended for U.S.
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Phase III J-ROCKET AF Study of Bayer s Xarelto (rivaroxaban) Meets Primary Endpoint
Review of Non-VKA Oral AntiCoagulants (NOACs) and their use in Great Britain
Review of Non-VKA Oral AntiCoagulants (NOACs) and their use in Great Britain Dr Alexander (Ander) Cohen Guy s and St Thomas Hospitals, King s College London, UK Pavia Spring Meeting 13 June 2014 Overview
Randomized, double-blind, parallel-group, multicenter, doubledummy
ABOUT RECORD STUDIES FAST FACTS RECORD is a global program of four trials in more than 12,500 patients, comparing Xarelto (rivaroxaban) and enoxaparin in the prevention of venous thromboembolism (VTE)
Published Ahead of Print on May 13, 2013 as 10.1200/JCO.2013.49.1118. J Clin Oncol 31. 2013 by American Society of Clinical Oncology INTRODUCTION
Published Ahead of Print on May 13, 2013 as 10.1200/JCO.2013.49.1118 The latest version is at http://jco.ascopubs.org/cgi/doi/10.1200/jco.2013.49.1118 JOURNAL OF CLINICAL ONCOLOGY A S C O S P E C I A L
Published Ahead of Print on April 4, 2011 as 10.1200/JCO.2010.32.8294. J Clin Oncol 29. 2011 by American Society of Clinical Oncology INTRODUCTION
Published Ahead of Print on April 4, 2011 as 10.1200/JCO.2010.32.8294 The latest version is at http://jco.ascopubs.org/cgi/doi/10.1200/jco.2010.32.8294 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E
Thrombosis and Hemostasis
Thrombosis and Hemostasis Wendy Lim, MD, MSc, FRCPC Associate Professor, Department of Medicine McMaster University, Hamilton, ON Overview To review the important developments in venous thromboembolism
How To Get A Dose Of Bayer Healthcare'S Oral Anticoagulant, Xarelto
News Release FOR UK HEALTHCARE MEDIA ONLY Bayer HealthCare Bayer plc Bayer House Strawberry Hill Newbury Berkshire, RG14 1JA www.bayer.co.uk Bayer s Xarelto (rivaroxaban) Recommended by CHMP for EU Approval
DATE: 06 May 2013 CONTEXT AND POLICY ISSUES
TITLE: Low Molecular Weight Heparins versus New Oral Anticoagulants for Long-Term Thrombosis Prophylaxis and Long-Term Treatment of DVT and PE: A Review of the Clinical and Cost-Effectiveness DATE: 06
Paul G. Lee. 2 ND YEAR RESEARCH ELECTIVE RESIDENT S JOURNAL Volume III, 1998-1999. A. Objective
A comparison of six months of anticoagulation with extended anticoagulation for a first episode of venous thromboembolism in patients with thrombophilia Paul G. Lee A. Objective a. To evaluate the risk
Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (AF) with one or more risk factors
News Release For use outside the US and UK only Bayer Pharma AG 13342 Berlin Germany Tel. +49 30 468-1111 www.bayerpharma.com Bayer s Xarelto Approved in the EU for the Prevention of Stroke in Patients
Bayer Pharma AG 13342 Berlin Germany Tel. +49 30 468-1111 www.bayerpharma.com. News Release. Not intended for U.S. and UK Media
News Release Not intended for U.S. and UK Media Bayer Pharma AG 13342 Berlin Germany Tel. +49 30 468-1111 www.bayerpharma.com Bayer Forms Collaboration with Academic and Governmental Institutions for Rivaroxaban
Inpatient Anticoagulation Safety. To provide safe and effective anticoagulation therapy through a collaborative approach.
Inpatient Anticoagulation Safety Purpose: Policy: To provide safe and effective anticoagulation therapy through a collaborative approach. Upon the written order of a physician, Heparin, Low Molecular Weight
New Oral Anticoagulants. How safe are they outside the trials?
New Oral Anticoagulants How safe are they outside the trials? Objectives The need for anticoagulant therapy Indications for anticoagulation Traditional anticoagulant therapies Properties of new oral anticoagulants
To provide an evidenced-based approach to treatment of patients presenting with deep vein thrombosis.
DEEP VEIN THROMBOSIS: TREATMENT TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To provide an evidenced-based approach to treatment of patients presenting with deep vein thrombosis.
NHS FORTH VALLEY RIVAROXABAN AS TREATMENT FOR DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM IN ADULTS
NHS FORTH VALLEY RIVAROXABAN AS TREATMENT FOR DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM IN ADULTS Date of First Issue 01/12/ 2012 Approved 15/11/2012 Current Issue Date 29/10/2014 Review Date 29/10/2016
Venous Thromboembolic Treatment Guidelines
Venous Thromboembolic Treatment Guidelines About the NYU Venous Thromboembolic Center (VTEC) The center s mission is to deliver advanced screening, detection, care, and management services for patients
New Real-World Evidence Reaffirms Low Major Bleeding Rates for Bayer s Xarelto in Patients with Non-Valvular Atrial Fibrillation
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Late-Breaking Science at ESC Congress 2015: New Real-World Evidence Reaffirms
Hot Line Session at European Society of Cardiology (ESC) Congress 2014:
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Hot Line Session at European Society of Cardiology (ESC) Congress 2014: Once-Daily
Thrombin generation and recurrent venous thromboembolism
Thrombin generation and recurrent venous thromboembolism T. Zhu, W. Ye, F. Dali Ali, L. Carcaillon, V. Remones, M. Alhenc Gelas, P. Gaussem, P.Y. Scarabin, J. Emmerich INSERM U765, University Paris Descartes,
NnEeWw DdEeVvEeLlOoPpMmEeNnTtSs IiıNn OoRrAaLl AaNnTtIiıCcOoAaGgUuLlAaTtIiıOoNn AaNnDd RrEeVvEeRrSsAaLl
NnEeWw DdEeVvEeLlOoPpMmEeNnTtSs IiıNn OoRrAaLl AaNnTtIiıCcOoAaGgUuLlAaTtIiıOoNn AaNnDd RrEeVvEeRrSsAaLl Mikele Wissing, RN June 2014 Introduction until recently, was the unrivaled medication for treatment
Disclosure. New Agents for Treatment of DVT. Prevalence of DVT VTE. Normal Hemostasis 7/17/2015. Mark Oliver, MD, RVT, RPVI,FSVU
New Agents for Treatment of DVT Disclosure PI Adopt and Amplify trials Mark Oliver, MD, RVT, RPVI,FSVU BMS and Pfizer Speaker VTE Venous Thromboembolism Recognized DVT s New : 170,000 Recurrent : 90,000
Anticoagulation at the end of life. Rhona Maclean Rhona.maclean@sth.nhs.uk
Anticoagulation at the end of life Rhona Maclean Rhona.maclean@sth.nhs.uk Content Anticoagulant Therapies Indications for anticoagulation Venous thromboembolism (VTE) Atrial Fibrillation Mechnical Heart
Outpatient Treatment of Deep Vein Thrombosis with Low Molecular Weight Heparin (LMWH) Clinical Practice Guideline August 2013
Outpatient Treatment of Deep Vein Thrombosis with Low Molecular Weight Heparin (LMWH) Clinical Practice Guideline August 2013 General Principles: There is compelling data in the medical literature to support
Direct Oral Anticoagulants for Acute Venous Thromboembolism: Closing the Circle?
Direct Oral Anticoagulants for Acute Venous Thromboembolism: Closing the Circle? Running title: Verhamme et al.; DOACs for acute venous thromboembolism Peter Verhamme, MD, PhD 1 ; Henri Bounameaux, MD
Low Molecular Weight Heparin. All Wales Medicines Strategy Group (AWMSG) Recommendations and advice
Low Molecular Weight Heparin All Wales Medicines Strategy Group (AWMSG) Recommendations and advice Starting Point Low Molecular Weight Heparin (LMWH): Inhibits factor Xa and factor IIa (thrombin) Small
More information for patients and caregivers can be accessed at http://www.xarelto-us.com/.
Janssen Research & Development Submits Application to U.S. FDA for XARELTO (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome RARITAN, DECEMBER 29, 2011 -
Long-term anticoagulation treatment for acute venous thromboembolism in patients with and without cancer
962 Schattauer 2011 Blood Coagulation, Fibrinolysis and Cellular Haemostasis Long-term anticoagulation treatment for acute venous thromboembolism in patients with and without cancer The SWIss Venous ThromboEmbolism
Dec. 9, 2013, 11:00 a.m. EST
Dec. 9, 2013, 11:00 a.m. EST Portola Pharmaceuticals Announces New Phase 2 Results Confirming Immediate, Dose-Dependent and Well-Tolerated Reversal of Anticoagulation Activity of XARELTO(R) (rivaroxaban)
How To Manage An Anticoagulant
PERI-OPERATIVE MANAGEMENT OF PATIENTS WHO ARE RECEIVING A NEW ORAL ANTICOAGULANT (DABIGATRAN, RIVAROXABAN, APIXABAN) TARGET AUDIENCE: All Canadian health care professionals, including primary care physicians,
MCHENRY WESTERN LAKE COUNTY EMS SYSTEM OPTIONAL CE ADVANCED LEVEL (EMTP, PHRN, ECRN) August 2013. Anticoagulants
MCHENRY WESTERN LAKE COUNTY EMS SYSTEM OPTIONAL CE ADVANCED LEVEL (EMTP, PHRN, ECRN) August 2013 Anticoagulants Anticoagulants are agents that prevent the formation of blood clots. Before we can talk about
New Anticoagulants: When and Why Should I Use Them? Disclosures
Winship Cancer Institute of Emory University New Anticoagulants: When and Why Should I Use Them? Christine L. Kempton, MD, MSc Associate Professor of Pediatrics and Hematology and Medical Oncology Hemophilia
New Anticoagulants for the Treatment of Thromboembolism With a little subplot on superficial thrombophlebitis. Mark Crowther
New Anticoagulants for the Treatment of Thromboembolism With a little subplot on superficial thrombophlebitis Mark Crowther 1 Disclosures Advisory Boards in last 24 months Pfizer, Alexion, Bayer, CSL Behring,
Thrombophilia. Steven R. Lentz, M.D. Ph.D. Carver College of Medicine The University of Iowa May 2003
Thrombophilia Steven R. Lentz, M.D. Ph.D. Carver College of Medicine The University of Iowa May 2003 Thrombophilia Hereditary and acquired risk factors for thrombosis Venous thromboembolism Arterial thromboembolism
Investor News. Not intended for U.S. and UK media
Investor News Not intended for U.S. and UK media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer s Xarelto (Rivaroxaban) Approved for the Treatment of Pulmonary Embolism
Bayer Extends Clinical Investigation of Rivaroxaban into Important Areas of Unmet Medical Need in Arterial Thromboembolism
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer Extends Clinical Investigation of Rivaroxaban into Important Areas of
6/19/2012. Update on Venous Thromboembolism Prophylaxis. Disclosure. Learning Objectives. No conflicts of interest to declare
Update on Venous Thromboembolism Prophylaxis Disclosure No conflicts of interest to declare Learning Objectives After completion of this presentation, participants should be able to: Define venous thromboembolism,
Traveller s Thrombosis. Dr. Peter Verhamme Vascular Medicine and Haemostasis UZ Leuven
Traveller s Thrombosis Dr. Peter Verhamme Vascular Medicine and Haemostasis UZ Leuven Case 1: To thromboprophylaxe or not Women, aged 49, BMI 29, Combined Oral Contraceptives. Family history of provoked
Treatment of Venous Thromboembolism in Cancer Patients
The role of low-molecular-weight heparin in cancer patients with acute venous thromboembolism and how it improves outcomes are discussed. Jacky Tiplady. Jersey Cottages. Photograph. Treatment of Venous
National Guidance and New Protocols
National Guidance and New Protocols Dr Jane Strong Consultant Haematologist DVT clinical lead Acute VTE chair DAWN AC Twentieth User Group Meeting 8 th October 2012 Autumn dawn Restless geese take flight
The management of cerebral hemorrhagic complications during anticoagulant therapy
The management of cerebral hemorrhagic complications during anticoagulant therapy Maurizio Paciaroni Stroke Unit Division of Cardiovascular Medicine University of Perugia - Italy Perugia Stroke Registry
USE AND INTERPRETATION OF LABORATORY COAGULATION TESTS IN PATIENTS WHO ARE RECEIVING A NEW ORAL ANTICOAGULANT (DABIGATRAN, RIVAROXABAN, APIXABAN)
USE AND INTERPRETATION OF LABORATORY COAGULATION TESTS IN PATIENTS WHO ARE RECEIVING A NEW ORAL ANTICOAGULANT (DABIGATRAN, RIVAROXABAN, APIXABAN) TARGET AUDIENCE: All Canadian health care professionals:
The importance of adherence and persistence: The advantages of once-daily dosing
The importance of adherence and persistence: The advantages of once-daily dosing Craig I. Coleman, PharmD Professor, University of Connecticut School of Pharmacy Storrs, CT, USA Conflicts of interest Dr
Position Statement: The Use of VTED Prophylaxis in Foot and Ankle Surgery
Position Statement: The Use of VTED Prophylaxis in Foot and Ankle Surgery Position Statement There is currently insufficient data for the (AOFAS) to recommend for or against routine VTED prophylaxis for
Disclosures. Overview. Anticoagulation in 2015: Where We Are and Where We Are Going. Impact of NOACs in Canada
Anticoagulation in 2015: Where We Are and Where We Are Going Jeffrey I Weitz, MD, FRCP(C), FACP Professor of Medicine and Biochemistry McMaster University Canada Research Chair in Thrombosis Heart & Stroke
News Release. Media contacts: Ernie Knewitz Tel: 908.927.2953 Mobile: 917.697.2318 eknewitz@its.jnj.com
News Release Media contacts: Ernie Knewitz Tel: 908.927.2953 Mobile: 917.697.2318 eknewitz@its.jnj.com Shaun Mickus Phone: 908.927.2416 Mobile: 973.476.7144 smickus@its.jnj.com Investor contacts: Stan
ACUTE DVT MANAGEMENT Richard J. DeMasi, MD April 26, 2014
ACUTE DVT MANAGEMENT Richard J. DeMasi, MD April 26, 2014 Thromboembolism epidemiology 5 million DVT s 900,000 PE s 290,000 fatalities Heit J. Blood. 2005;106:910. 10 VTE events Since this talk began DVT
Bios 6648: Design & conduct of clinical research
Bios 6648: Design & conduct of clinical research Section 1 - Specifying the study setting and objectives 1. Specifying the study setting and objectives 1.0 Background Where will we end up?: (a) The treatment
Dabigatran (Pradaxa) Guidelines
Dabigatran (Pradaxa) Guidelines Dabigatran is a new anticoagulant for reducing the risk of stroke in patients with atrial fibrillation. Dabigatran is a direct thrombin inhibitor, similar to warfarin, without
08/03/2015. Anticoagulation in the Elderly: Using New Direct Acting Oral Anticoagulants (DOACs) Indications for Anticoagulation
Anticoagulation in the Elderly: Using New Direct Acting Oral Anticoagulants (DOACs) Steven Zweig, MD, MSPH MU School of Medicine MU Interdisciplinary Center on Aging Caring for the Frail Elderly Conference
National Guidance and New Protocols
National Guidance and New Protocols Dr Jane Strong Consultant Haematologist DVT clinical lead Acute VTE chair DAWN AC Twentieth User Group Meeting 8 th October 2012 DVT patient pathway Assessment Diagnosis
Xabans Good for What Ails Ya? Brian Tiffany, MD, PhD, FACEP Dept of Emergency Medicine Chandler Regional Medical Center Mercy Gilbert Medical Center
Xabans Good for What Ails Ya? Brian Tiffany, MD, PhD, FACEP Dept of Emergency Medicine Chandler Regional Medical Center Mercy Gilbert Medical Center DISCLOSURES No relevant financial disclosures I will
2/17/2015 ANTICOAGULATION UPDATE OBJECTIVES BRIEF REVIEW: CLASSES OF ORAL ANTICOAGULANTS
ANTICOAGULATION UPDATE C AR R I E P AL M E R, D N P, RN, AN P - BC OBJECTIVES At the end of the presentation, the NP will be able to: Identify new indications for target-specific oral anticoagulants (TSOACs),
Oral anticoagulants new and old: bleeding risk and management strategies. Logan Tinsen Pharm.D. Benefis Hospitals
Oral anticoagulants new and old: bleeding risk and management strategies Logan Tinsen Pharm.D. Benefis Hospitals Disclaimer! I am not receiving any compensation from any drug company! Any opinions I may
New Oral Anticoagulants: Topic Brief
New Oral Anticoagulants: Topic Brief June 9, 2015 High-Level Research Question In patients with nonvalvular atrial fibrillation (AF) or venous thromboembolic disease, or who have undergone surgery for
EINSTEIN DVT/PE IMPORTANT SAFETY INFORMATION
EINSTEIN DVT/PE % INDICATIONS is indicated for the treatment of deep vein thrombosis (DVT). is indicated for the treatment of pulmonary embolism (PE). is indicated for the reduction in the risk of recurrence
Time of Offset of Action The Trial
New Antithrombotic Agents DISCLOSURE Relevant Financial Relationship(s) Speaker Bureau - None Consultant Amgen Tom DeLoughery, MD FACP FAWM Oregon Health and Sciences University What I am Talking About
Troubled by warfarin s narrow therapeutic index, numerous
Jeremy W. Vandiver, PharmD, BCPS; Douglas Faulkner, MD; Michael Erlandson, MD; Mary Onysko, PharmD, BCPS University of Wyoming School of Pharmacy, Laramie (Drs. Vandiver and Onysko); Hampden Medical Group,
DISCLOSURES CONFLICT CATEGORY. No conflict of interest to disclose
DISCLOSURES CATEGORY Employment Research support Scientific advisory board Consultancy Speakers bureau Major stockholder Patents Honoraria Travel support Other CONFLICT No conflict of interest to disclose
Verification of Participation & Certificate Request 28 th Annual Congress Phoenix, Arizona November 6 9, 2014
Complete this form in its entirety to claim the credits commensurate with your participation at the ACP s 28 th Annual Congress. You can only claim credit for one session if it runs concurrently with others.
Medication Policy Manual. Topic: Eliquis, apixaban Date of Origin: July 12, 2013. Committee Approval Date: July 11, 2014 Next Review Date: July 2015
Medication Policy Manual Policy No: dru313 Topic: Eliquis, apixaban Date of Origin: July 12, 2013 Committee Approval Date: July 11, 2014 Next Review Date: July 2015 Effective Date: August 1, 2014 IMPORTANT
Clinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
NHS FIFE WIDE POLICY - HAEMATOLOGY MANAGEMENT OF ANTICOAGULATION THERAPY DURING MAJOR AND MINOR ELECTIVE SURGERY
MANAGEMENT OF ANTICOAGULATION THERAPY DURING MAJOR AND MINOR ELECTIVE SURGERY The scope of this guideline is to simplify the management of patients on oral anticoagulation undergoing major and minor surgery.
Clinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
CDEC FINAL RECOMMENDATION
CDEC FINAL RECOMMENDATION RIVAROXABAN (Xarelto Bayer Inc.) New Indication: Pulmonary Embolism Note: The Canadian Drug Expert Committee (CDEC) previously reviewed rivaroxaban for the treatment of deep vein
Evaluation of von Willebrand factor and Factor VIII levels in multiple myeloma patients treated with Thalidomide
chapter 7 Evaluation of von Willebrand factor and Factor VIII levels in multiple myeloma patients treated with Thalidomide A.M.W. van Marion* J.A. Auwerda* T. Lisman P. Sonneveld H.M. Lokhorst F.W.G. Leebeek
STROKE PREVENTION IN ATRIAL FIBRILLATION
STROKE PREVENTION IN ATRIAL FIBRILLATION OBJECTIVE: To guide clinicians in the selection of antithrombotic therapy for the secondary prevention of ischemic stroke and arterial thromboembolism in patients
The New Oral Anticoagulants: When and When Not to Use Them Philip C. Comp, M.D., Ph.D. Professor of Medicine, University of Oklahoma Health Sciences
The New Oral Anticoagulants: When and When Not to Use Them Philip C. Comp, M.D., Ph.D. Professor of Medicine, University of Oklahoma Health Sciences Center September 25, 2015 Question: With which of the
THE INTERNET STROKE CENTER PRESENTATIONS AND DISCUSSIONS ON STROKE MANAGEMENT
THE INTERNET STROKE CENTER PRESENTATIONS AND DISCUSSIONS ON STROKE MANAGEMENT Stroke Prevention in Atrial Fibrillation Gregory Albers, M.D. Director Stanford Stroke Center Professor of Neurology and Neurological
What Does Pregnancy Have to Do With Blood Clots in a Woman s Legs?
Patient s Guide to Prevention of Blood Clots During Pregnancy: Use of Blood-Thinning A Patient s Guide to Prevention of Blood Clots During Pregnancy: Use of Blood-Thinning Drugs to Prevent Abnormal Blood
Module 1: Orthopedic Surgery: Disease State
XARELTO Product Brief ORS Rivaroxaban tablets Course Summary Module 1: Orthopedic Surgery: Disease State Orthopedic Surgery: Overview Pain and altered function of the hip and knee, due to conditions such
Implementation of NICE TAs 261 and 287
Corby Clinical Commissioning Group Kettering General Hospital NHS Trust Nene Clinical Commissioning Group Northampton General Hospital NHS Trust Northamptonshire Healthcare Foundation Trust Implementation
Cardiovascular Disease
Cardiovascular Disease 1 Cardiovascular Disease 1. More target specific oral anticoagulants (TSOAC) 2. Vorapaxar (Zonivity) 3. Continued noise about a polypill 4. WATCHMAN 3 1 2 3 4 Left Atrial Appendage
Clinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
The Effect of Anticoagulants on Cancer Progression and Survival
Thrombosis Decision Making and Problem Solving Anticoagulant treatment and survival in cancer patients. The evidence from clinical studies Ramón Lecumberri José A. Páramo Eduardo Rocha The association
Planning: Patient Goals and Expected Outcomes The patient will: Remain free of unusual bleeding Maintain effective tissue perfusion Implementation
Obtain complete heath history including allergies, drug history and possible drug Assess baseline coagulation studies and CBC Assess for history of bleeding disorders, GI bleeding, cerebral bleed, recent
NHS FORTH VALLEY Rivaroxaban for Stroke Prevention in Atrial Fibrillation
NHS FORTH VALLEY Rivaroxaban for Stroke Prevention in Atrial Fibrillation Date of First Issue 06/06/2012 Approved 06/06/2012 Current Issue Date 29/10/2014 Review Date 29/10/2016 Version 1.4 EQIA Yes 01/06/2012
ELSO GUIDELINES FOR TRAINING AND CONTINUING EDUCATION OF ECMO SPECIALISTS
ELSO GUIDELINES FOR TRAINING AND CONTINUING EDUCATION OF ECMO SPECIALISTS PURPOSE The "" is a document developed by the Extracorporeal Life Support Organization (ELSO) as a reference for current and future
New Oral Anticoagulants Increase Risk for Gastrointestinal Bleeding - A Systematic Review and Meta-Analysis
New Oral Anticoagulants Increase Risk for Gastrointestinal Bleeding - A Systematic Review and Meta-Analysis Holster IL, Valkhoff VE, Kuipers EJ, Tjwa ET Departments of Gastroenterology and Hepatology,
Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism
Implementation of NICE TA 261 Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism Contents 1. Executive summary 2. Introduction
La Profilassi del Tromboembolismo Venoso in Medicina
La Profilassi del Tromboembolismo Venoso in Medicina Claudio Cimminiello U.O. Medicina Interna Azienda Ospedaliera di Vimercate Decisions regarding prophylaxis in nonsurgical patients should be made after
Joseph A. Caprini, MD, MS, FACS, RVT
Joseph A. Caprini, MD, MS, FACS, RVT Louis W. Biegler Chair of Surgery NorthShore University HealthSystem, Evanston, IL Clinical Professor of Surgery University of Chicago Pritzker School of Medicine,
Critical Bleeding Reversal Protocol
Critical Bleeding Reversal Protocol Coagulopathy, either drug related or multifactorial, is a major contributing factor to bleeding related mortality in a variety of clinical settings. Standard therapy
1 Table of Contents 1.1 List of Tables 1.2 List of Figures 2 Introduction 3 Global Peripheral Vascular Devices Market - Market Characterization 3.
1 Table of Contents 1.1 List of Tables 1.2 List of Figures 2 Introduction 3 Global Peripheral Vascular Devices Market - Market Characterization 3.1 Peripheral Vascular Devices Market, Revenue ($m), 2004-3.2
J Clin Oncol 25:5490-5505. 2007 by American Society of Clinical Oncology INTRODUCTION
VOLUME 25 NUMBER 34 DECEMBER 1 2007 JOURNAL OF CLINICAL ONCOLOGY A S C O S P E C I A L A R T I C L E American Society of Clinical Oncology Guideline: Recommendations for Venous Thromboembolism Prophylaxis